How to buy ObsEva stock

ObsEva SA is a biotechnology business based in the US. ObsEva shares (OBSV) are listed on the NASDAQ and all prices are listed in US Dollars. ObsEva employs 42 staff and has a trailing 12-month revenue of around 0.00.

ObsEva share price

Use our graph to track the performance of OBSV stocks over time.

ObsEva shares at a glance

• Key figures

Information last updated 2021-03-10.

52-week range	$1.63 - $6.30
50-day moving average	$3.93
200-day moving average	$2.74
Wall St. target price	$11.67
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-2.28

Buy ObsEva shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy ObsEva stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of ObsEva SA by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

ObsEva financials

Revenue TTM	$17,000
Gross profit TTM	$17,000
Return on assets TTM	-58.81%
Return on equity TTM	-289.54%
Profit margin	0%
Book value	$0.15
Market capitalisation	$255.2 million

TTM: trailing 12 months

Shorting ObsEva shares

There are currently 2.3 million ObsEva shares held short by investors – that's known as ObsEva's "short interest". This figure is 4.6% up from 2.2 million last month.

There are a few different ways that this level of interest in shorting ObsEva shares can be evaluated.

ObsEva's "short interest ratio" (SIR)

ObsEva's "short interest ratio" (SIR) is the quantity of ObsEva shares currently shorted divided by the average quantity of ObsEva shares traded daily (recently around 12.7 million). ObsEva's SIR currently stands at 0.18. In other words for every 100,000 ObsEva shares traded daily on the market, roughly 180 shares are currently held short.

However ObsEva's short interest can also be evaluated against the total number of ObsEva shares, or, against the total number of tradable ObsEva shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case ObsEva's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 ObsEva shares in existence, roughly 30 shares are currently held short) or 0.0424% of the tradable shares (for every 100,000 tradable ObsEva shares, roughly 42 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against ObsEva.

Find out more about how you can short ObsEva stock.

ObsEva share dividends

We're not expecting ObsEva to pay a dividend over the next 12 months.

ObsEva share price volatility

Over the last 12 months, ObsEva's shares have ranged in value from as little as $1.63 up to $6.3. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while ObsEva's is 0.8342. This would suggest that ObsEva's shares are less volatile than average (for this exchange).

ObsEva overview

ObsEva SA, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. The company is developing Linzagolix, an oral gonadotropin-releasing hormone receptor antagonist for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. It also is developing OBE022, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age; and Nolasiban, an oral oxytocin receptor antagonist to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization. The company was founded in 2012 and is headquartered in Geneva, Switzerland. .

Frequently asked questions

• What percentage of ObsEva is owned by insiders or institutions?

  Currently 5.542% of ObsEva shares are held by insiders and 48.495% by institutions.

• How many people work for ObsEva?

  Latest data suggests 42 work at ObsEva.

• When does the fiscal year end for ObsEva?

  ObsEva's fiscal year ends in December.

• Where is ObsEva based?

  ObsEva's address is: Chemin des Aulx, 12, Geneva, Switzerland, 1228

• What is ObsEva's ISIN number?

  ObsEva's international securities identification number is: CH0346177709

• What is ObsEva's CUSIP number?

  ObsEva's Committee on Uniform Securities Identification Procedures number is: H5861P103